| ORBIMED ADVISORS LLC | Director · 10% owner | 1.41% | 1,126,126 | Apr 21, 2026 |
| RA Capital Management, L.P. | 10% owner | 8.11% | 6,475,882 | Apr 27, 2026 |
| 667, L.P. | Director · 10% owner | — | — | — |
| Baker Bros. Advisors (GP) LLC | Director · 10% owner | — | — | — |
| Baker Bros. Advisors LP | Director · 10% owner | — | — | Jun 9, 2026 |
| Baker Brothers Life Sciences LP | Director · 10% owner | — | — | — |
| BAKER FELIX | Director · 10% owner | — | — | — |
| BAKER JULIAN | Director · 10% owner | — | — | — |
| Brusky Sean P. | Chief Business Officer | — | — | — |
| Combs Andrew | Chief Chemistry Officer | — | — | Feb 4, 2026 |
| FRIEDMAN PAUL A | Director | — | — | Jun 9, 2026 |
| Kolchinsky Peter | 10% owner | — | — | — |
| Lim Bryant David | CLO, CFO, Corp Sec. | — | — | Feb 4, 2026 |
| OrbiMed Capital GP VI LLC | Director · 10% owner | — | — | — |
| ORBIMED CAPITAL LLC | Director · 10% owner | — | — | — |
| OrbiMed Genesis GP LLC | Director · 10% owner | — | — | — |
| RA Capital Healthcare Fund LP | 10% owner | — | — | — |
| Scherle Peggy | Chief Scientific Officer | — | — | Feb 4, 2026 |
| Shah Rajeev M. | 10% owner | — | — | — |
| Vaddi Krishna | CEO · Director | — | — | Feb 4, 2026 |